Literature DB >> 25363430

Contemporary health care economics: an overview.

Nancy McLaughlin1, Michael K Ong, Victor Tabbush, Farhad Hagigi, Neil A Martin.   

Abstract

Economic evaluations provide a decision-making framework in which outcomes (benefits) and costs are assessed for various alternative options. Although the interest in complete and partial economic evaluations has increased over the past 2 decades, the quality of studies has been marginal due to methodological challenges or incomplete cost determination. This paper provides an overview of the main types of complete and partial economic evaluations, reviews key methodological elements to be considered for any economic evaluation, and reviews concepts of cost determination. The goal is to provide the clinician neurosurgeon with the knowledge and tools needed to appraise published economic evaluations and to direct high-quality health economic evaluations.

Keywords:  CBA = cost-benefit analysis; CEA = cost-effectiveness analysis; CMA = cost minimization analysis; CUA = cost-utility analysis; EQ-5D = EuroQol 5 Dimension; HCUP = Healthcare Cost and Utilization Project; ICER = incremental cost-effectiveness ratio; NIS = Nationwide Inpatient Sample; QALY; QALY = quality-adjusted life year; accounting; cost; cost analysis; cost-benefit; cost-effectiveness; cost-utility; economic evaluation

Mesh:

Year:  2014        PMID: 25363430     DOI: 10.3171/2014.8.FOCUS14455

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  2 in total

1.  Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.

Authors:  Khachapon Nimdet; Surachat Ngorsuraches
Journal:  BMJ Open       Date:  2015-10-05       Impact factor: 2.692

2.  The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.

Authors:  Jesper Jørgensen; Spiros Servos; Panos Kefalas
Journal:  J Mark Access Health Policy       Date:  2018-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.